Cancer Research Meeting Calendar  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 34, 2159-2164, September 1, 1974]
© 1974 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Philpott, G. W.
Right arrow Articles by Parker, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Philpott, G. W.
Right arrow Articles by Parker, C. W.

Affinity Cytotoxicity of Tumor Cells with Antibody-Glucose Oxidase Conjugates, Peroxidase, and Arsphenamine1

Gordon W. Philpott, Richard J. Bower, Keith L. Parker, William T. Shearer and Charles W. Parker

Departments of Surgery [G. W. P., R. J. B.] and Medicine [K. L. P., W. T. S., C. W. P.], Washington University School of Medicine, St. Louis, Missouri 63110

Selective cytotoxicity was accomplished in two antibody-tumor cell models with antibody-glucose oxidase conjugates (Ab-GO) followed by treatment with horseradish peroxidase (HRP) and arsphenamine. The two cell models used were hapten [2,4,6-trinitrophenyl (TNP)]-substituted HeLa and HEp-2 cells with specifically purified antihapten (TNP) antibody and human colonic carcinoma cells (HT-29) with immunoglobulin G anti-carcinoembryonic antigen antibody. Brief treatment of TNP cells with anti-TNP antibody conjugated to glucose oxidase (0.07 to 70 µg/ml) followed by culture in medium with HRP (50 µg/ml) and arsphenamine (1 to 10 µg/ml) resulted in zero to 100% cell killing when compared with controls in a microcytotoxicity assay. Cytotoxicity was reduced or absent when (a) any of the three components (Ab-GO, HRP, or arsphenamine) were omitted; (b) cells not substituted with TNP were used; or (c) free hapten (dinitrophenyl-lysine) inhibited Ab-GO binding to TNP cells. Affinity cytotoxicity (73 to 90%) was also seen in HT-29 cells treated with anti-CEA antibody conjugated to glucose oxidase followed by treatment in HRP and arsphenamine (1 to 10 µg/ml). CEA, extracted from malignant ascitic fluid with perchloric acid, partially inhibited the cytotoxic action of the Ab-GO system, and normal goat immunoglobulin G-glucose oxidase caused significantly less killing, showing the selectivity of the reaction.

1 Supported by Grant 5R01-CA12626 from the National Cancer Institute.

Received 3/ 7/74. Accepted 5/ 6/74.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1974 by the American Association for Cancer Research.